Company: ELV
Filing Date: 2025-07-17
Form Type: 10-Q
Source: 0001156039-25-000114
Chunk: 70

Company: Elevance Health, Inc.
Filing Date: 2025-07-17
Form: 10-Q
Item: Item 8
Chunk 70
---
329 — 329 Changes in securities lending payable466 320 146 Proceeds from issuance of common stock under employee stock plans21 157 (136)Changes in bank overdrafts631 — 631 Total sources of cash4,518 5,881 (1,363)Uses of Cash:Purchases of investments, net of proceeds from sales, maturities, calls and redemptions— (1,415)1,415 Purchases of subsidiaries, net of cash acquired— (1,124)1,124 Repurchase and retirement of common stock(1,258)(1,029)(229)Purchases of property and equipment(463)(602)139 Repayments of short- and long-term debt, net of issuances(1,255)— (1,255)Cash dividends(771)(757)(14)Changes in securities lending collateral(466)(321)(145)Changes in bank overdrafts— (479)479 Other uses of cash, net(35)(157)122 Total uses of cash(4,248)(5,884)1,636 Effect of foreign exchange rates on cash and cash equivalents2 (5)7 Net increase (decrease) in cash and cash equivalents$272 $(8)$280 

The increase in net cash provided by operating activities was primarily due to favorable working capital impacts, partially offset by a lower net income for the six months ended June 30, 2025.

Other significant sources of cash year-over-year included increased proceeds from sales, maturities, calls, and redemptions of investments, net of purchases, changes in bank overdrafts, lower amounts for purchase of subsidiaries, net of cash acquired and decreased purchases of property and equipment. Other significant uses of cash year-over-year included an increase in repayments of short- and long-term debt, net of issuances and increased amounts for repurchase and retirement of common stock.

We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $35,879 at June 30, 2025. Since December 31, 2024, total cash, cash equivalents and investments in fixed maturity and equity securities increased by $163, primarily due to cash generated from operations, decline in purchase of subsidiaries, net of cash acquired, an increase in proceeds from sales, maturities, calls and redemptions of investments, net